Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial
Circulation · 21.04.2026 · 153 (16) · 1196-1209
DOI: 10.1161/circulationaha.125.079023 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 21.04.2026. Verfasst von Yunli Shen und 58 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Cardiovascular Diseases, Shanghai Arrhythmia Research Center, and Department of Cardiology, Shanghai East Hospital, School of…. Hauptthemen laut MEDLINE: Memantine, Atrial Premature Complexes, Excitatory Amino Acid Antagonists. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Premature atrial contractions (PACs) are independently associated with atrial fibrillation, stroke, and heart failure, yet no pharmacological therapy is approved for PAC suppression. Experimental studies have identified a functional cardiac glutamatergic system in which N-methyl-D-aspartate receptors regulate atrial electrophysiology. Preclinical studies show that pharmacological antagonism of N-methyl-D-aspartate receptors with memantine suppresses atrial arrhythmias. METHODS: We conducted an investigator-initiated, phase 2, multicenter, randomized, double-blind, placebo-controlled trial. Symptomatic adults with frequent PACs (≥1000/24 h) were randomly assigned to receive memantine or placebo for 6 weeks. The primary end point was the percentage change in mean 24-hour PAC count from baseline to the end of treatment. The primary analysis was performed in the intention-to-treat population. Prespecified secondary end points included the responder rate (≥50% PAC reduction), percentage change in nonsustained atrial tachycardia burden, and cumulative incidence of new-onset atrial fibrillation. RESULTS: Among 241 patients included in the efficacy analysis, memantine resulted in a greater reduction in PAC count than placebo (between-group difference, 47.1 percentage points; P =0.0045). The responder rate was higher with memantine than with placebo (52.4% versus 23.1%; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Cardiovascular Diseases, Shanghai Arrhythmia Research Center, and Department of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, China (Y.S., W.H., D.X., D.L., Y. Liu, B…
- Department of Cardiology, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China (C.Z., B. Zhou, J. Zeng, X.Y.).
- Department of Cardiology, The First Hospital of China Medical University, Shenyang (Y.S., G.S., S.Z., X.G.).
- State Key Laboratory of Transvascular Implantation Devices, Heart Regeneration and Repair Key Laboratory of Zhejiang Province, and Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang U…
- Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, China (B. Yu, S.L., N.L.).
- Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (X.C., M.Z., Yiyi Wang, Xiajun Hu).
ORCID-Profile: Yingxian Sun, Jian'an Wang, Bo Yu, Xiang Cheng, Xiaogang Guo, Yue Li, Wei Han, Bingqing Zhou, Zhaoqi Huang, Yigang Li, Guosheng Fu, Dandan Liang, Bing Yang, Dechun Yin, Guozhe Sun, Shu Zhang, Xiaofan Guo, Yiyi Wang, Xiajun Hu, Shufeng Li, Ning Li, Feng Hu, Xinyang Hu, Cong Zeng, Jian Yang, Yan Wang, Luyun Wang, Guanghua Wang, Jun Pu, Changsheng Ma, Yi-Han Chen
Zitieren
APA
Shen, Y., Zeng, C., Sun, Y., Wang, J., Yu, B., Cheng, X., Guo, X., Wang, D. W., Li, Y., Han, W., Zhou, B., Sheng, H., Huang, Z., Li, Y., Fu, G., Zhang, J., Xie, D., Liang, D., Liu, Y., …, & Chen, Y. H. (2026). Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial. Circulation, 153(16), 1196-1209. https://doi.org/10.1161/circulationaha.125.079023
Vancouver
Shen Y, Zeng C, Sun Y, Wang J, Yu B, Cheng X, et al. Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial. Circulation. 2026;153(16):1196-1209. doi:10.1161/circulationaha.125.079023
BibTeX
@article{Shen2026,
author = {Shen, Yunli and Zeng, Chunyu and Sun, Yingxian and Wang, Jian'an and Yu, Bo and Cheng, Xiang and Guo, Xiaogang and Wang, Dao Wen and Li, Yue and Han, Wei and Zhou, Bingqing and Sheng, Hongzhuan and Huang, Zhaoqi and Li, Yigang and Fu, Guosheng and Zhang, Jidong and Xie, Duanyang and Liang, Dandan and Liu, Yi and Yang, Bing and Zhang, Qi and Duan, Ran and Li, Hongxiao and Zhang, Baowei and Wu, Yizhang and Zheng, Liang and He, Jia and Liu, Shenglin and Yin, Dechun and Sun, Guozhe and Zhang, Shu and Guo, Xiaofan and Zhang, Min and Wang, Yiyi and Hu, Xiajun and Zeng, Jing and Yang, Xiaoli and Li, Shufeng and Li, Ning and Hu, Feng and Wang, Haifeng and Hu, Xinyang and Wang, Yaping and Zeng, Cong and Wang, Kai and Yang, Jian and Wang, Yan and Lai, Jinsheng and Wang, Luyun and Xiong, Ke and Wang, Guanghua and Zou, Qicheng and Shao, Beihua and Chen, Zhiwen and Wu, Yahan and Leng, Junwei and Pu, Jun and Ma, Changsheng and Chen, Yi-Han},
title = {Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial},
journal = {Circulation},
year = {2026},
volume = {153},
number = {16},
pages = {1196--1209},
doi = {10.1161/circulationaha.125.079023}
}
EUVIMED